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0.1-0.3%, similar to a laparoscopic 
cholecystectomy. Obesity is the 
primary risk factor for type 2 DM (Chan 
et al. 1994). DM is a chronic metabolic 
disorder which if left untreated may 
lead to serious complications and 
death. Until the advent of bariatric 
surgery, the mainstay treatment for DM 
in the morbidly obese includes diet 
control, oral hypoglycaemic agents 
and insulin. One of the main aims 
of treatment for DM is to prevent the 
development and progression of micro 
and macrovascular disease. A 1 percent 
reduction in HbA1c results in 14%, 37% 
and 21% reduction in macrovascular, 
microvascular and deaths related to 
DM respectively. Remission of DM is 
a common effect seen after bariatric 
surgery in the obese diabetics patients 
(Buchwald et al. 2009). While the initial 
believe that remission of DM was due 
to weight loss and reduction in insulin 
resistance, current evidence show that 
remission of DM is apparent even 
before significant weight loss occurs 
suggesting a more complex neuro-
hormonal regulation involvement. It is 
believed that several enteral hormones 
Obesity is a life-long, progressive, life-
threatening, costly, genetically-related, 
multi-factorial disease of excess fat 
storage with multiple co-morbidities. 
Bariatric Surgery is currently the most 
effective therapy available for morbid 
obesity and can result in improvement 
or complete resolution of obesity 
related co-morbidities including 
diabetes mellitus (DM) (Buchwald et al. 
2009). Current indication for bariatric 
surgery are BMI of more than 35 with 
co-morbidities, BMI of more than 40 
without co-morbidities, having failed 
conservative method of weight loss 
with no serious psychiatric disorders. 
There are several different types of 
bariatric surgery which includes purely 
restrictive procedure such as adjustable 
gastric bands, sleeve gastrectomy and 
gastric plication, combined restrictive 
and malabsorptive procedure such 
as gastric bypass and finally pure 
malabsorptive procedure such as 
mini-gastric bypass, bilio-pancreatic 
diversion and duodenal switch. The 
advent of laparoscopic technique has 
resulted in improvement of its safety 
profile with a 30 day mortality of 
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are produced following surgeries like 
sleeve gastrectomy and gastric bypass. 
The amelioration of DM which occur 
sooner (within four days of surgery) 
than associated weight loss was in 
fact first noted and reported in 1955 
following a subtotal gastrectomy with 
a loop gastro-jejunostomy (Friedman 
et al. 1955). The foregut (Rubino et 
al. 2006), hindgut (Patriti et al. 2005), 
ghrelin hormones and weight loss are 
thought to be the main mechanism of 
action of remission of DM following 
surgery. Furthermore, it was identified 
that  the main gut hormones involved 
in the entero-insular axis are GLP-
1 (Glucagon-like peptide-1) and GIP 
(Gastric Inhibitory Polypeptide) which 
are also called ‘incretins’, Whilst 
ghrelin and PYY (peptide YY) seems to 
play a less prominent role in glucose 
homeostasis (Papamargaritis et al. 
2013). Currently there is compelling 
evidence from clinical studies such 
as the STAMPEDE (Schauer et al. 
2014), SOS (Swedish Obese Subject 
Trial) (Sjostrom et al. 2012) and recent 
systematic review and meta-analysis 
(Buchwald et al. 2009) that supported 
the superiority and effectiveness of 
bariatric surgery in the amelioration 
of DM when compared to medical 
therapy alone. In 2011, a position 
statement made by the International 
Diabetes Federation (IDF) recommends 
surgery for diabetic patients with a BMI 
of more than 35 whom have not achieve 
treatment targets with medical therapy 
and in under some circumstances 
patients with a BMI between 30 to 35 
should be eligible for surgery. Hence, 
is bariatric surgery the cure for diabetes 
mellitus? It all depends on how we see 
and perceived. The definition of ‘cure’ 
means complete eradication for life. 
Based on the overwhelming clinical 
evidence, beyond doubt complete 
resolution of type 2 DM is achievable, 
however as shown in the SOS trial 
where 50% relapse occurred at 10 
years follow-up due to multifactorial 
reasons, whether this is sustainable 
life-long is questionable. Still, there are 
many questions to be answered. One 
thing which is clear is the important 
role of bariatric surgery in achieving 
a significant and sustainable weight 
loss, partial and complete remission 
in type 2 DM of close to 80% and 
other metabolic related problems 
with significant quality of life and cost 
economics outcome (Buchwald et al. 
2009, Klein et al. 2009).
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